Literature DB >> 15170732

Decline of surface MHC I by adenoviral gene transfer of anti-MHC I intrabodies in human endothelial cells-new perspectives for the generation of universal donor cells for tissue transplantation.

Florian Beyer1, Cornelia Doebis, Annette Busch, Thomas Ritter, Abner Mhashilkar, Wayne M Marasco, Horst Laube, Hans-Dieter Volk, Martina Seifert.   

Abstract

BACKGROUND: The seeding of small-calibre vascular polytetrafluoroethylene (PTFE) grafts with endothelial cells provides an increase in biocompatibility of the graft surface. The harvest and ex vivo culture of autologous endothelial cells is highly delicate. Allogeneic human umbilical vein endothelial cells (HUVEC) could be a potential cell source-however, rejection might occur due to major histocompatibility complex (MHC) I mismatches. Lowering cell surface MHC I expression on endothelial cells by gene transfer of an anti-MHC I intrabody might reduce graft failure. The intrabody consists of a single-chain variable fragment (sFv) of an anti-MHC I antibody, carrying a terminal KDEL sequence to retain the molecule together with the MHC I inside the endoplasmic reticulum.
METHODS: Adenoviral gene transfer was used to express the intrabody in HUVEC. The MHC I surface expression was measured 48 h after transduction by flow cytometry. Functional effects of the intrabody expression were analyzed in a calcein release cytotoxicity assay.
RESULTS: A transduction efficiency of more than 95% with EGFP-adenovirus indicates a sufficient gene transfer into HUVEC. Intrabody-adenovirus-transduced HUVEC show a massive reduction in MHC I surface expression creating almost a complete 'knockout' phenotype. Stimulation with inflammatory cytokines could not overcome this effect. The cell lysis of anti-MHC I intrabody-expressing HUVEC in a cytotoxicity assay is reduced when compared with the level of the MHC mismatched control.
CONCLUSIONS: Our data indicate that HUVEC with reduced levels of MHC I might be used as universal donor cells for the seeding of vascular grafts. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170732     DOI: 10.1002/jgm.548

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  10 in total

Review 1.  Potential applications of intracellular antibodies (intrabodies) in stem cell therapeutics.

Authors:  Boon Chin Heng; David Michael Kemeny; Hua Liu; Tong Cao
Journal:  J Cell Mol Med       Date:  2005 Jan-Mar       Impact factor: 5.310

2.  Permanent, lowered HLA class I expression using lentivirus vectors with shRNA constructs: Averting cytotoxicity by alloreactive T lymphocytes.

Authors:  K Haga; N A Lemp; C R Logg; J Nagashima; E Faure-Kumar; G G Gomez; C A Kruse; R Mendez; R Stripecke; N Kasahara; N A Kasahara; J C Cicciarelli
Journal:  Transplant Proc       Date:  2006-12       Impact factor: 1.066

3.  Suppression of HLA expression by lentivirus-mediated gene transfer of siRNA cassettes and in vivo chemoselection to enhance hematopoietic stem cell transplantation.

Authors:  Katrin Hacke; Rustom Falahati; Linda Flebbe-Rehwaldt; Noriyuki Kasahara; Karin M L Gaensler
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 4.  Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?

Authors:  Paul Lohan; Cynthia M Coleman; J Mary Murphy; Matthew D Griffin; Thomas Ritter; Aideen E Ryan
Journal:  Stem Cell Res Ther       Date:  2014-08-19       Impact factor: 6.832

5.  An intrabody specific for the nucleophosmin carboxy-terminal mutant and fused to a nuclear localization sequence binds its antigen but fails to relocate it in the nucleus.

Authors:  Chiara Martinelli; Emanuela Colombo; Daniele Piccini; Cristina Sironi; Pier Giuseppe Pelicci; Ario de Marco
Journal:  Biotechnol Rep (Amst)       Date:  2014-05-27

6.  Ex Vivo Major Histocompatibility Complex I Knockdown Prolongs Rejection-free Allograft Survival.

Authors:  Jessica B Chang; William J Rifkin; Marc A Soares; April Duckworth; Nakul Rao; Yee Cheng Low; Jonathan P Massie; Piul S Rabbani; Pierre B Saadeh; Daniel J Ceradini
Journal:  Plast Reconstr Surg Glob Open       Date:  2018-06-11

7.  Generation of functional scFv intrabody to abate the expression of CD147 surface molecule of 293A cells.

Authors:  Khajornsak Tragoolpua; Nutjeera Intasai; Watchara Kasinrerk; Sabine Mai; Yuan Yuan; Chatchai Tayapiwatana
Journal:  BMC Biotechnol       Date:  2008-01-29       Impact factor: 2.563

Review 8.  Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER.

Authors:  Thomas Böldicke
Journal:  J Cell Mol Med       Date:  2007 Jan-Feb       Impact factor: 5.310

Review 9.  Specific in vivo knockdown of protein function by intrabodies.

Authors:  Andrea L J Marschall; Stefan Dübel; Thomas Böldicke
Journal:  MAbs       Date:  2015-08-07       Impact factor: 5.857

Review 10.  A Short History of Skin Grafting in Burns: From the Gold Standard of Autologous Skin Grafting to the Possibilities of Allogeneic Skin Grafting with Immunomodulatory Approaches.

Authors:  Frederik Schlottmann; Vesna Bucan; Peter M Vogt; Nicco Krezdorn
Journal:  Medicina (Kaunas)       Date:  2021-03-02       Impact factor: 2.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.